user warning: Got error 28 from storage engine query: SELECT t.* FROM term_node r INNER JOIN term_data t ON r.tid = t.tid INNER JOIN vocabulary v ON t.vid = v.vid WHERE r.vid = 437992 ORDER BY v.weight, t.weight, t.name in /var/www/www.fnno.com/htdocs/modules/taxonomy/taxonomy.module on line 617.

Analyst Rating In Review: Endo Pharmaceuticals Bid Up 8.6% Since Downgraded 7 Days Ago (ENDP)

Published on Thu, 02/07/2013 - 10:09
By Robert Cotter

A week ago, Oppenheimer downgraded Endo Pharmaceuticals from Outperform to Perform. The stock closed at $30.66, which is 8.6% higher than the price one week ago ($28.23).

In the past 52 weeks, shares of Endo Pharmaceuticals have traded between a low of $25.00 and a high of $44.53 and are now at $30.40, which is 22% above that low price. Over the last five market days, the 200-day moving average (MA) has gone down 0.2% while the 50-day MA has advanced 0.7%.

There is potential upside of 9.6% for shares of Endo Pharmaceuticals based on a current price of $30.40 and an average consensus analyst price target of $33.31. The stock should find initial support at its 200-day moving average (MA) of $30.27 and further support at its 50-day MA of $27.56.

Endo Pharmaceuticals Holdings Inc. is a specialty pharmaceutical company with products that provide pain management. The Company researches, develops, produces, and markets both branded and generic pharmaceuticals. Endo's products include Percocet, Percodan, and Lidoderm.

By Robert Cotter
rcotter@fnno.com